WHAT IS CLAIMED IS:

1. A humanized anti-secreted frizzled-related protein 2 (SFRP2) antibody or antigen binding fragment thereof which binds SFRP2, wherein said humanized antibody or antigen binding fragment thereof comprises a variable heavy (VH) chain polypeptide and a variable light (VL) chain polypeptide comprising the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 9, respectively.

2. A humanized anti-secreted frizzled-related protein 2 (SFRP2) antibody or antigen binding fragment thereof which binds SFRP2, wherein said humanized antibody or antigen binding fragment thereof comprises a complementary determining region (CDR) H1 comprising the amino acid sequence of SEQ ID NO:19, a CDR H2 comprising the amino acid sequence of SEQ ID NO:20, a CDR H3 comprising the amino acid sequence of SEQ ID NO:21, a CDR L1 comprising the amino acid sequence of SEQ ID NO:22, a CDR L2 comprising the amino acid sequence of SEQ ID NO:23, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:24.

3. A humanized anti-secreted frizzled-related protein 2 (SFRP2) antibody or antigen binding fragment thereof which binds SFRP2, wherein said humanized antibody or antigen binding fragment thereof comprises a heavy chain polypeptide and a light chain polypeptide comprising the amino acid sequences of SEQ ID NO: 15 and SEQ ID NO: 16, respectively.

4. The humanized antibody or antigen binding fragment thereof of claim 1 or claim 2, wherein the humanized antibody or antigen-binding fragment comprises a heavy chain constant region and a light chain constant region.

5. The humanized antibody or antigen binding fragment thereof of any one of the foregoing claims, wherein the humanized antibody or antigen-binding fragment is a monoclonal antibody.

6. The humanized antibody or antigen binding fragment thereof of any one of the foregoing claims, which is a full length antibody.

7. The humanized antibody or antigen binding fragment thereof of any one of the foregoing claims, which is a humanized antigen binding fragment.

8. The humanized antibody or antigen binding fragment thereof of any one of the foregoing claims, wherein said humanized antibody or antigen binding fragment thereof comprises an IC50 value of 0.7 or less relative to the IC50 value of an antibody or antigen binding fragment thereof comprising a VH chain polypeptide and VL chain polypeptide of SEQ ID NOs: 10 and 11, respectively wherein the IC50 values are measured by an ELISA assay.

9. An isolated polynucleotide comprising a nucleic acid molecule encoding the heavy chain variable region or heavy chain of the humanized antibody or antigen-binding fragment thereof of any one of claims 1-8.

10. The isolated polynucleotide of claim 9, wherein the nucleic acid molecule encodes the VH of SEQ ID NO: 2.

11. An isolated polynucleotide comprising a nucleic acid molecule encoding the light chain variable region or light chain of the humanized antibody or antigen-binding fragment thereof of any one of claims 1-8.

12. The isolated polynucleotide of claim 11, wherein the nucleic acid molecule encodes the VL of SEQ ID NO: 9.

13. An isolated polynucleotide comprising a nucleic acid molecule encoding the heavy chain variable region or heavy chain of the humanized antibody or antigen-binding fragment thereof of any one of claims 1-8 and the light chain variable region or light chain of the humanized antibody or antigen-binding fragment thereof of any one of claims 1-8.

14. An isolated vector comprising the polynucleotide of any one of claims 9-13.

15. A host cell comprising (a) the polynucleotide of any one of claims 9-13, (b) the vector of claim 14, or (c) a first vector comprising the polynucleotide of claim 9 or 10 and a second vector comprising the polynucleotide of claim 11 or 12.

16. The host cell of claim 15, which is selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, yeast, CHO, YB/20, NS0, PER-C6, HEK-293T, NIH-3T3, HeLa, BHK, Hep G2, SP2/0, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, BMT10 cell, plant cell, insect cell, and human cell in tissue culture.

17. The host cell of claim 15 or claim 16, wherein the host cell is a CHO cell.

18. A method of producing a humanized antibody or antigen-binding fragment thereof that binds to SFRP2 comprising culturing the host cell of any one of claims 14-17 so that the nucleic acid molecule is expressed and the humanized antibody or antigen-binding fragment thereof is produced, optionally wherein the method further comprises isolating the humanized antibody or antigen-binding fragment thereof from the culture.

19. The method of claim 18, wherein the isolated humanized antibody or antigen-binding fragment thereof is substantially free of precipitates.

20. An isolated humanized antibody or antigen-binding fragment thereof that specifically binds to secreted frizzled related protein 2 (SFRP2) and is encoded by the polynucleotide of any one of claims 9-13 or produced by the method of claim 18.

21. A pharmaceutical composition comprising a therapeutically effective amount of the humanized antibody or antigen-binding fragment thereof of any one of claims 1-8 and 20 and a pharmaceutically acceptable excipient.

22. Use of the pharmaceutical composition of claim 21 in the manufacture of a medicament for~~A method of~~ treating cancer in a patient, ~~the method comprising~~wherein ~~administering to the patient~~ the pharmaceutical composition ~~of claim 21~~is to be administered to the patient.

23. The ~~method~~ use of claim 22, wherein the cancer is a breast cancer, an angiosarcoma, an osteosarcoma, a rhabdomyosarcoma, an alveolar soft part sarcoma, a malignant glioma, a multiple myeloma, a renal cell carcinoma, a kidney cancer, a prostate cancer, a lung cancer, a melanoma, a non-small cell lung cancer, a pancreatic cancer, a colorectal cancer, a bladder cancer, a hepatocellular carcinoma, a sarcoma, and a gastrointestinal cancer.

24. The ~~method~~ use of any one of claims 22-23, ~~further comprising administering~~wherein an antagonist of an inhibitory immune checkpoint molecule is to be administered, optionally wherein the immune checkpoint molecule is PD-1.

25. The ~~method~~ use of claim 24, wherein the antagonist of PD-1 is an anti-PD-1 antibody or antigen-binding fragment thereof, optionally wherein the anti-PD-1 antibody or antigen-

binding fragment thereof is selected from the group consisting of nivolumab, pembrolizumab, MEDI-0680 (AMP-514), camrelizumab (SHR-1210), tislelizumab (BGB-A317), and spartalizumab (NPVPDR001, NVS240118, PDR001).

~~25.~~26. The humanized antibody or antigen-binding fragment thereof of any one of claims 1-8 and 20 for use in therapy.